smoothened mutation confers resistance hedgehog pathway inhibitor medulloblastoma 
hedgehog hh signaling pathway inappropriately activated certain human cancers including medulloblastoma aggressive brain tumor gdc- drug inhibits hh signaling targeting serpentine receptor smoothened smo produced promising anti-tumor responses early clinical studies cancers driven mutations pathway evaluate mechanism resistance medulloblastoma patient relapsed initial response gdc- determined mutational status hh signaling genes tumor disease progression identified amino acid substitution conserved aspartic acid residue smo effect hh signaling disrupted ability gdc- bind smo suppress pathway mutation altering amino acid also arose gdc--resistant mouse model medulloblastoma findings show acquired mutations serpentine receptor features g protein-coupled receptor can serve mechanism drug resistance human cancer 
